Short answer
OMEROS CORP (OMER) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Omeros reported financial results for the three and nine months ended September 30, 2026.
OMEROS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Omeros reported financial results for the three and nine months ended September 30, 2026
- Detailed financial figures and management commentary appear in Exhibit 99.1 accompanying the 8-K
Item EX-99.1 · Exhibit EX-99.1
- YARTEMLEA Q3 gross revenue $41.8M, up 29.6% sequentially, with net revenue $35.9M, supporting commercial momentum
- Positive operating cash flow $13.3M and cash plus short-term investments $95.3M, improving near-term funding capacity
- GAAP net loss $57.4M driven mainly by a $62.0M non-cash derivative loss, while adjusted net income reached $4.7M
- 2029 Note repurchases reduced principal outstanding to approximately $40.3M, eliminated $8.6M interest, and reduced potential shares by 4.9M
- EMA CHMP reaffirmed a negative opinion on European narsoplimab approval, limiting near-term international expansion prospects
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OMEROS CORP 8-K filings
Get the next OMER 8-K as it lands
Follow OMER for push alerts, or ask the research agent what this filing means.